Drug Trial Radar · NCT06716216
A Study of BGM0504 in Participants With Type 2 Diabetes
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
553
Actual
Start
Jan 13, 2025
Primary completion
Aug 25, 2026
Study completion Aug 25, 2026
Sponsor
- Lead sponsor
- BrightGene Bio-Medical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd.
- First posted
- Dec 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is conducted in China. The aim of the trial is to evaluate the efficacy and safety of BGM0504 versus semaglutide as add-on to metformin and/or sulfonylureas in patients with type 2 diabetes
Conditions
- Type 2 Diabetes Mellitus (T2DM)
Interventions
Drug: 5 mg BGM0504 Administered SCDrug
Experimental: 5 mg BGM0504 5 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week.
Drug:10 mg BGM0504 Administered SCDrug
Experimental: 10 mg BGM0504 10 mg BGM0504 administered SC once a week.
Drug: Semaglutide Administered SCDrug
Active Comparator: 1 mg Semaglutide 1 mg semaglutide administered SC once a week
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Hemoglobin A1c (HbA1c)Time frame: Week 0 to Week 32
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University People's Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.